Table 2.
short G-CSF | pegfilgrastim | p-value | |
---|---|---|---|
Cycle | 84 | 53※1 | |
No. of patients※2 | 29 | 19 | |
Age | n (%) | n (%) | |
median | 35 | 42 | 0.74 |
range | 14–66 | 18–55 | |
primary tumor | |||
testis | 25 (86) | 17 (89) | 0.72 |
anterior mediastinum | 3 (10) | 2 (11) | |
retroperitoneum | 1 (4) | 0 | |
pathology | |||
seminoma | 13 (44) | 8 (42) | 0.69 |
mixed | 15 (51) | 11 (58) | |
unknown | 1 (5) | 0 | |
clinical stage | 0.15 | ||
I | 0 | 3 (15) | |
II | 13 (44) | 8 (42) | |
III | 15 (51) | 7 (36) | |
unknown | 1 (5) | 1 (5) | |
IGCCC | 0.30 | ||
Good | 15 (51) | 14 (73) | |
Intermediate | 8 (27) | 4 (21) | |
Poor | 5 (22) | 1 (6) | |
distant metastasis | 0.47 | ||
LN | 23 (79) | 15 (79) | |
Lung | 7 (24) | 4 (21) | |
Liver | 1 (3) | 2 (10) | |
Bone | 0 | 2 (10) | |
Retroperitoneum | 1 (3) | 0 | |
None | 3 (10) | 3 (15) |
IGCCC, International Germ Cell Consensus Classification.
※1. 9 of 53 cycles were combined with G-CSF.
※2. The total number of patients was 44, of which 4 had overlapping patient numbers as some patients belonged to both groups.